Insider · CIK 0001788393
Kamal Adawi
Files at XGN (EXAGEN INC.), FATE (FATE THERAPEUTICS INC). First filing Feb 8, 2024, latest Mar 6, 2024.
In brief
Kamal Adawi files SEC Form 4 as CFO at XGN (EXAGEN INC.), and also at FATE (FATE THERAPEUTICS INC). Since Feb 8, 2024, Kamal Adawi has reported 0 open-market buys worth $0 and 2 open-market sells worth $38k, the latest filed on Mar 6, 2024.
A track record needs three past buys with six months of prices behind them; Kamal Adawi has 0, so none is measured yet.
The newest scored trade: sold $24k of XGN on Mar 4, 2024, filed Mar 6, 2024, scored 22 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XGN: EXAGEN INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | XGNsell EXAGEN INC. | $24k 12,784 shares | -5% | +31% from low-45% from high | |
| 22Weak | XGNsell EXAGEN INC. | $13k 6,738 shares | -4% | +39% from low-42% from high |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | FATE FATE THERAPEUTICS INC | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 100,000 | Jan 16, 2026 |
| Jan 15, 2026 | FATE FATE THERAPEUTICS INC | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jan 16, 2026 |
| Oct 20, 2025 | FATE FATE THERAPEUTICS INC | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 75,000 | Oct 21, 2025 |
| Oct 20, 2025 | FATE FATE THERAPEUTICS INC | AGrant or award Stock Option (Right to Buy)derivative | +375,000 | $0.00 | $0 | 375,000 | Oct 21, 2025 |
| Mar 4, 2024 | XGN EXAGEN INC. | SOpen-market sale Common Stock | -9,297 | $1.91 | $18k | 247,236 | Mar 6, 2024 |
| Mar 4, 2024 | XGN EXAGEN INC. | SOpen-market sale Common Stock | -3,487 | $1.91 | $6,660 | 243,749 | Mar 6, 2024 |
| Feb 20, 2024 | XGN EXAGEN INC. | AGrant or award Common Stock | +75,000 | $0.00 | $0 | 256,533 | Feb 22, 2024 |
| Feb 6, 2024 | XGN EXAGEN INC. | SOpen-market sale Common Stock | -6,738 | $1.95 | $13k | 181,533 | Feb 8, 2024 |
Questions about Kamal Adawi
Answered from the filings on this page, as of the latest one.
Is Kamal Adawi buying or selling?
Not in the last 12 months. Kamal Adawi's latest open-market trade on SEC Form 4 was sold $24k of XGN on Mar 4, 2024.
How did Kamal Adawi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kamal Adawi has 0.
Where does Kamal Adawi file Form 4?
Kamal Adawi has filed Form 4 at XGN (EXAGEN INC.) as CFO and Corporate Secretary; FATE (FATE THERAPEUTICS INC) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.